Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled Dosage Escalation Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted in HIV-uninfected, Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs EOD-GT8 60mer (Primary) ; AS01B
- Indications HIV infections
- Focus Adverse reactions; First in man
- 11 May 2022 Status changed from active, no longer recruiting to completed.
- 15 Nov 2021 Planned End Date changed from 31 Dec 2020 to 22 Nov 2021.
- 14 Apr 2021 According to a Moderna Therapeutics media release, Dr. William Schief presented data from this study at the International AIDS Society HIV Research for Prevention (HIVR4P) virtual conference